Zydus Lifesciences Adjusts Evaluation Amid Strong Financial Performance and Market Challenges

May 13 2025 08:18 AM IST
share
Share Via
Zydus Lifesciences has recently adjusted its evaluation score, reflecting its strong management efficiency with a 19.00% return on equity and a low debt-to-equity ratio of 0.09. The company has reported consistent positive results over seven quarters, despite facing a challenging year in the stock market.
Zydus Lifesciences has recently undergone an evaluation adjustment, reflecting a revision in its score. This adjustment comes amid a backdrop of notable financial metrics and market positioning within the Pharmaceuticals & Drugs industry.

The company has demonstrated strong management efficiency, highlighted by a return on equity (ROE) of 19.00%. Additionally, Zydus Lifesciences maintains a low debt-to-equity ratio of 0.09 times, indicating a solid financial structure. The operating profit has shown healthy growth, with an annual increase of 22.23%. Over the past seven consecutive quarters, the company has reported positive results, further underscoring its operational stability.

Despite a challenging year, where the stock has generated a return of -9.82%, Zydus Lifesciences has seen its profits rise by 33.2%. The price-to-earnings growth (PEG) ratio stands at 0.6, suggesting a fair valuation relative to its earnings growth. However, technical indicators currently place the stock in a mildly bearish range, with certain metrics reflecting a cautious outlook.

For those interested in tracking the latest developments, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News